Teva scores rare partial win in CMS price negotiation appeal

In challenging IRA price negotiations, Teva Pharmaceuticals has gained a partial win as the U.S. Court of Appeals for Washington, D.C., sent a previous ruling back to a lower court for further review. The challenge surrounds the way the CMS determines “bona fide marketing” for a generic or biosimilar drug.